$14,439.99 consulting Payment -- Bayer Healthcare to Dr. Jessica Moore

Cardiologist Jessica Moore Receives $14,439.99 Consulting Fee from Bayer for Xarelto

This page provides a detailed analysis of a $14,439.99 consulting payment from Bayer Healthcare to Dr. Jessica Moore. Data is from the CMS Open Payments (Sunshine Act) database.

Payment Details

FieldValue
Amount$14,439.99
Payment Typeconsulting
Payment NatureConsulting Fee
Pharmaceutical CompanyBayer Healthcare
PhysicianDr. Jessica Moore
NPI Number1777701738
Physician SpecialtyCardiology
LocationCity, AL
Date of Payment2025-01-25
Related Drug/DeviceXarelto
Conflict AssessmentHigh -- Significant

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Bayer Healthcare made a $14.4K consulting payment to Jessica Moore, a Cardiology specialist in City, AL. The payment was associated with Xarelto. The total payment of $14,439.99 to Dr. Jessica Moore from Bayer Healthcare for consulting services related to Xarelto is a significant amount. This payment was made on January 25, 2025, indicating a recent engagement between the physician and the pharmaceutical company. The payment is categorized as a 'Consulting Fee' for services related to the drug Xarelto, suggesting a focus on its development, promotion, or clinical application.

Patient Guidance: What This Payment Means for You

If you are a patient prescribed Xarelto, understand that your cardiologist may receive payments from the drug manufacturer for consulting services, which is a standard practice in the industry. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

For a Cardiology specialty, a consulting fee of $14,439.99 from a major pharmaceutical company like Bayer for services related to a specific drug like Xarelto is considered a high-value payment, potentially above average for routine consulting.

Regulatory Context: Sunshine Act Requirements

This payment falls under the Sunshine Act provisions of the Affordable Care Act, requiring disclosure of financial relationships between drug manufacturers and healthcare providers.

Related Topics

This payment is related to the following healthcare transparency topics:

Understanding consulting Payments

Consulting payments are made when pharmaceutical companies hire physicians as advisors or consultants. This can include serving on advisory boards, providing expert medical opinions on drug development or marketing strategies, and reviewing clinical data. Consulting is one of the most common forms of pharmaceutical payment to physicians and can range from a few hundred dollars for a brief consultation to tens of thousands of dollars for ongoing advisory relationships.

Frequently Asked Questions About This Payment

What was this $14.4K payment for?

This was a consulting payment of $14.4K from Bayer Healthcare to Jessica Moore, categorized as "Consulting Fee". It was associated with Xarelto. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Jessica Moore accept pharmaceutical money?

Yes, Jessica Moore received this $14.4K payment from Bayer Healthcare. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Jessica Moore's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this consulting payment?

A consulting payment of $14.4K may reflect legitimate advisory services the physician provides. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Cardiology?

To compare this payment against Cardiology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Cardiology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Jessica Moore's relationship with Bayer Healthcare?

The payment amount is substantial, warranting further investigation into the nature and duration of the consulting services. This $14.4K consulting payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Cardiology?

The specific drug, Xarelto, is a well-known anticoagulant, suggesting the consulting may involve clinical trial data, market insights, or educational content.

What should patients do after learning about this payment?

If you are a patient prescribed Xarelto, understand that your cardiologist may receive payments from the drug manufacturer for consulting services, which is a standard practice in the industry.

What else should I know about this consulting payment?

The payment date indicates a current or very recent relationship between Dr. Moore and Bayer Healthcare.

Related Reports

Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.